Your browser is no longer supported. Please, upgrade your browser.
Settings
LMNL [NASD]
Liminal BioSciences Inc.
Index- P/E- EPS (ttm)-3.50 Insider Own66.40% Shs Outstand29.94M Perf Week-10.67%
Market Cap92.00M Forward P/E- EPS next Y-1.43 Insider Trans0.00% Shs Float10.06M Perf Month-24.68%
Income-90.60M PEG- EPS next Q-0.42 Inst Own0.30% Short Float3.91% Perf Quarter-41.75%
Sales1.90M P/S48.42 EPS this Y65.80% Inst Trans- Short Ratio0.37 Perf Half Y-36.03%
Book/sh0.10 P/B29.30 EPS next Y-119.70% ROA-99.80% Target Price3.57 Perf Year-87.68%
Cash/sh0.55 P/C5.35 EPS next 5Y- ROE-382.40% 52W Range2.84 - 24.56 Perf YTD-30.24%
Dividend- P/FCF- EPS past 5Y43.90% ROI-118.10% 52W High-88.07% Beta1.77
Dividend %- Quick Ratio2.20 Sales past 5Y-33.00% Gross Margin44.30% 52W Low3.17% ATR0.17
Employees251 Current Ratio2.40 Sales Q/Q0.00% Oper. Margin- RSI (14)28.71 Volatility5.36% 5.18%
OptionableYes Debt/Eq18.97 EPS Q/Q42.30% Profit Margin- Rel Volume0.04 Prev Close2.94
ShortableYes LT Debt/Eq17.10 EarningsMay 17 AMC Payout- Avg Volume1.06M Price2.93
Recom3.20 SMA20-16.03% SMA50-26.53% SMA200-35.61% Volume45,637 Change-0.34%
Jun-24-21Downgrade H.C. Wainwright Buy → Neutral
Jun-02-21Downgrade Piper Sandler Overweight → Neutral $22 → $4.50
Feb-18-21Initiated H.C. Wainwright Buy $11
Dec-21-20Initiated Piper Sandler Overweight $22
Jul-09-21 04:00PM  
Jun-23-21 08:30AM  
08:30AM  
Jun-04-21 04:27PM  
04:27PM  
03:30PM  
03:30PM  
May-28-21 04:30PM  
May-24-21 01:13PM  
May-21-21 04:45PM  
04:45PM  
May-17-21 04:30PM  
04:30PM  
08:30AM  
08:30AM  
May-05-21 03:00PM  
Mar-28-21 12:40AM  
Mar-24-21 04:39PM  
Mar-17-21 08:46AM  
Mar-12-21 12:30PM  
Mar-04-21 12:38PM  
Feb-12-21 09:00AM  
08:30AM  
Feb-11-21 03:10PM  
Jan-27-21 06:00PM  
Jan-21-21 08:30AM  
Jan-12-21 09:00AM  
Dec-15-20 09:20AM  
09:20AM  
Dec-01-20 08:00AM  
Nov-13-20 09:20AM  
Nov-12-20 04:57PM  
04:57PM  
Nov-10-20 06:33PM  
06:33PM  
Nov-08-20 07:01PM  
Nov-06-20 09:26AM  
Nov-05-20 04:35AM  
04:35AM  
Oct-30-20 08:30AM  
08:30AM  
Oct-07-20 09:30AM  
Sep-21-20 08:16AM  
08:16AM  
Sep-09-20 08:00AM  
Sep-08-20 06:00AM  
Sep-01-20 08:36AM  
08:36AM  
Aug-25-20 08:49AM  
Aug-24-20 01:30PM  
10:03AM  
Aug-10-20 05:01PM  
Aug-06-20 05:01PM  
Jul-22-20 07:55AM  
Jul-17-20 08:00AM  
Jul-02-20 11:16AM  
Jun-30-20 05:31PM  
05:31PM  
05:00PM  
05:00PM  
Jun-11-20 05:00PM  
Jun-09-20 03:53PM  
03:53PM  
May-28-20 05:30PM  
May-22-20 07:14AM  
May-13-20 05:00PM  
Mar-23-20 06:30AM  
Mar-22-20 03:23PM  
03:23PM  
Mar-20-20 05:01PM  
05:01PM  
05:00PM  
Feb-12-20 07:30AM  
07:30AM  
Feb-06-20 07:30AM  
Jan-13-20 07:00AM  
07:00AM  
Dec-23-19 03:43PM  
Nov-28-19 04:40PM  
04:40PM  
Nov-27-19 07:30AM  
Nov-25-19 12:03PM  
Nov-18-19 07:30AM  
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma-Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050), which is in Phase 1 for the treatment of idiopathic pulmonary fibrosis and respiratory diseases. The Plasma-Derived Therapeutics segment focused on the development of its plasma-derived product candidate Ryplazim, a purified glu-plasminogen derived from human plasma that acts as a plasminogen replacement therapy for patients deficient in plasminogen protein. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.